TipRanks
Advertisement
Advertisement
Verrica Pharmaceuticals CEO buys $125.8K in common stock
PremiumThe FlyVerrica Pharmaceuticals CEO buys $125.8K in common stock
29d ago
Verrica: Buy Rating Reiterated on YCANTH Momentum, Pivotal Wart Program Progress, and Strengthened Balance Sheet; $12 Price Target Maintained
Premium
Ratings
Verrica: Buy Rating Reiterated on YCANTH Momentum, Pivotal Wart Program Progress, and Strengthened Balance Sheet; $12 Price Target Maintained
1M ago
Stacy Ku Reiterates Buy on Verrica as Ycanth’s Strong Uptake and Wart Expansion Opportunity Support Long-Term Growth
Premium
Ratings
Stacy Ku Reiterates Buy on Verrica as Ycanth’s Strong Uptake and Wart Expansion Opportunity Support Long-Term Growth
1M ago
Verrica Pharmaceuticals Earnings Call Highlights Growth, Strain
PremiumCompany AnnouncementsVerrica Pharmaceuticals Earnings Call Highlights Growth, Strain
4M ago
Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)
Premium
The Fly
Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)
4M ago
Verrica Pharmaceuticals: Focused Ycanth Rollout and Underpenetrated Pediatric Market Drive Attractive Risk‑Reward and Support Buy Rating
Premium
Ratings
Verrica Pharmaceuticals: Focused Ycanth Rollout and Underpenetrated Pediatric Market Drive Attractive Risk‑Reward and Support Buy Rating
6M ago
Verrica Pharmaceuticals Launches Ycanth for treatment of Molluscum in Japan
PremiumThe FlyVerrica Pharmaceuticals Launches Ycanth for treatment of Molluscum in Japan
7M ago
YCANTH Phase 3 Wart Study Puts Verrica in Focus While Veeva Extends Its Clinical Footprint
Premium
Company Announcements
YCANTH Phase 3 Wart Study Puts Verrica in Focus While Veeva Extends Its Clinical Footprint
8M ago
Verrica announces first patient dosed in program evaluating YCANTH
Premium
The Fly
Verrica announces first patient dosed in program evaluating YCANTH
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100